scispace - formally typeset
V

Vincent Meininger

Researcher at Aventis Pharma

Publications -  180
Citations -  16470

Vincent Meininger is an academic researcher from Aventis Pharma. The author has contributed to research in topics: Amyotrophic lateral sclerosis & Riluzole. The author has an hindex of 57, co-authored 175 publications receiving 14803 citations. Previous affiliations of Vincent Meininger include University of Cambridge.

Papers
More filters
Journal ArticleDOI

A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis

TL;DR: The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset, according to a prospective, double-blind, placebo-controlled trial in 155 outpatients with Amyotrophicateral sclerosis.
Journal ArticleDOI

TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis

TL;DR: Findings further corroborate that TDP-43 is involved in ALS pathogenesis and reports eight missense mutations in nine individuals—six from individuals with sporadic ALS and three from those with familial ALS (FALS)—and a concurring increase of a smaller T DP-43 product.
Journal ArticleDOI

Dose-ranging study of riluzole in amyotrophic lateral sclerosis

TL;DR: A double-blind, placebo-controlled, multicentre study to confirm that riluzole is well tolerated and lengthens survival of patients with ALS and suggests that the 100 mg dose of rILuzole has the best benefit-to-risk ratio.
Journal ArticleDOI

Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis

Wouter van Rheenen, +187 more
- 01 Sep 2016 - 
TL;DR: Evidence of ALS being a complex genetic trait with a polygenic architecture is established and the SNP-based heritability is estimated at 8.5%, with a distinct and important role for low-frequency variants (frequency 1–10%).